HK Stock Market Move | MIRXES-B(02629) rose by over 35% in the afternoon, with miRNA technology empowering non-invasive early screening for gastric cancer receiving high industry recognition.

MIRXES-B(02629) rose more than 35% in the afternoon, hitting a 32.99% increase as of the time of publication, with a price of 16.73 Hong Kong dollars and a trading volume of 4.98 billion Hong Kong dollars. On the news front, on March 23, the 23rd China International Exhibition on Clinical Laboratory, Medicine, and Blood Transfusion Equipment (CACLP) successfully concluded at the Xiamen International Exhibition Center. Mirxes, with its leading miRNA testing technology and professional cancer early screening solutions, became the focus of the exhibition. In particular, the core product MiXiaoWei received significant attention. It is reported that this product has completed prospective clinical validation in nearly ten thousand individuals, with excellent performance in testing. It has been successfully approved in multiple countries and regions including Singapore, China, and the European Union, filling a market gap in non-invasive gastric cancer early screening. It is worth noting that at the end of February this year, Mirxes announced a memorandum of understanding with Apollo Health and Lifestyle, a wholly-owned subsidiary of the Indian Apollo Group, to jointly develop and commercialize advanced cancer early screening solutions in India and surrounding countries. They plan to establish a joint venture company with a valuation of no less than 50 million US dollars.